These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34063325)

  • 1. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.
    Wu KJ; Li SH; Liao JB; Chiou CC; Wu CS; Chen CC
    Biology (Basel); 2021 May; 10(5):. PubMed ID: 34063325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
    Tang M; Gu XZ; Wu PC; Yang XT
    J Inflamm Res; 2022; 15():2775-2787. PubMed ID: 35518839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary intraosseous Rosai-Dorfman disease: An analysis of clinicopathologic characteristics, molecular genetics, and prognostic features.
    Weng X; Yang Y; Zhang M; Cai C; Sun Y; Wu X; Zhang R; Gui H; Li W; Xu Q; Liu X
    Front Oncol; 2022; 12():950114. PubMed ID: 36185213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
    Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
    Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
    Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
    Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosai-Dorfman Disease between Proliferation and Neoplasia.
    Elbaz Younes I; Sokol L; Zhang L
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation.
    Garces S; Medeiros LJ; Marques-Piubelli ML; Coelho Siqueira SA; Miranda RN; Cuglievan B; Sriganeshan V; Medina AM; Garces JC; Saluja K; Bhattacharjee MB; Khoury JD; Li S; Xu J; Jelloul FZ; Thakral B; Cameron Yin C
    Hum Pathol; 2022 Mar; 121():36-45. PubMed ID: 34995673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical
    Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
    Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
    Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.
    Akram AM; Chaudhary A; Kausar H; Althobaiti F; Abbas AS; Hussain Z; Fatima N; Zafar E; Asif W; Afzal U; Yousaf Z; Zafar A; Harakeh SM; Qamer S
    Saudi J Biol Sci; 2021 Jul; 28(7):3735-3740. PubMed ID: 34220225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O; Yalcin S
    Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.
    Rutkowski P; Gos A; Jurkowska M; Switaj T; Dziewirski W; Zdzienicki M; Ptaszyński K; Michej W; Tysarowski A; Siedlecki JA
    Oncol Lett; 2014 Jul; 8(1):47-54. PubMed ID: 24959217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
    Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
    JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
    Pereira TDSF; de Amorim LSD; Pereira NB; Vitório JG; Duarte-Andrade FF; Guimarães LM; Diniz MG; Gomes CC; Gomez RS
    J Oral Pathol Med; 2019 Nov; 48(10):906-910. PubMed ID: 31310691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.